Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk

Major molecular response induced by nilotinib as first line treatment in a LMC patient with intermediate Sokal risk

Authors

  • Ursula Sessa Ematologia, AO Cardarelli, Napoli
  • Maria Celentano Ematologia, AO Cardarelli, Napoli
  • Stefano Rocco Ematologia, AO Cardarelli, Napoli
  • Rossella Fabbricini Ematologia, AO Cardarelli, Napoli
  • Olimpia Finizio Ematologia, AO Cardarelli, Napoli
  • Vincenzo Mettivier Ematologia, AO Cardarelli, Napoli


DOI:

https://doi.org/10.7175/cmi.v6i2S.1138

Keywords:

Chronic myeloid leukemia, Optimal response, Nilotinib

Abstract

Here we describe a case of a man with chronic myeloid leukemia at intermediate risk, according to the Sokal index. After cytoreduction with hydroxyurea, the patient started nilotinib at standard dose (600 mg/day) obtaining a complete haematological response after one month of treatment.After about 3 months the patient presented a complete cytogenetic response and after six months major molecular response (MR3). At nine months of treatment the patient presented a complete molecular response (MR4).

Downloads

Published

2015-10-13

Issue

Section

Case report
Loading...